INTRODUCTION
Hematopoietic stem and progenitor cells (HSPCs) reside in specific niches that control survival, proliferation, self-renewal, or differentiation in the bone marrow (BM). Stem cells closely associate with spindle-shaped N-cadherin-and Angiopoietin-1-expressing osteoblasts that line the endosteal bone (Calvi et al., 2003; Zhang et al., 2003; Arai et al., 2004) . In normal individuals, the continuous trafficking of HSPCs between the BM and blood compartments likely fills empty or damaged niches and contributes to the maintenance of normal hematopoiesis (Wright et al., 2001; Abkowitz et al., 2003) . Although it has been known for many years that the egress of HSPCs can be enhanced by multiple agonists, the mechanisms that regulate this critical process are largely unknown.
The hematopoietic cytokine granulocyte-colony stimulating factor (G-CSF) is widely used clinically to elicit HSPC mobilization for life-saving BM transplantation and has thus served as the prototype to gain mechanistic insight about this phenomenon (Lapidot and Petit, 2002; Papayannopoulou, 2004) . While mice deficient in the G-CSF receptor (G-CSFR of attracting HSPCs (Wright et al., 2002) , and its disruption is sufficient to induce mobilization (Broxmeyer et al., 2005) . However, the function of these proteases has been challenged by other data, indicating that G-CSF-induced mobilization was normal in mice lacking virtually all neutrophil serine protease activity, even when combined with a broad metalloproteinase inhibitor (Levesque et al., 2004) . This suggests that other proteases and/or other mechanisms are involved.
We and others have previously shown that the sulfated fucose polymer fucoidan can rapidly elicit HSPC mobilization (Frenette and Weiss, 2000; Sweeney et al., 2000) . We were intrigued by the similar biological characteristics of fucoidan, which is synthesized by certain seaweeds, and sulfatide, a sulfated galactolipid synthesized by mammalian cells (Roberts et al., 1986; Skinner et al., 1991; Waddell et al., 1995) . The synthesis of sulfatide and its nonsulfated form, galactosylceramide (GalCer), is initiated by the addition of UDP-galactose to ceramide in a reaction mediated by UDP-galactose:ceramide galactosyltransferase (Cgt), an enzyme highly expressed in oligodendrocytes and Schwann cells (Sprong et al., 1998) . The products of Cgt, collectively referred to as galactocerebrosides (GCs), are a major component of the myelin sheaths that facilitate the transmission of saltatory conduction (Norton and Cammer, 1984) . Predictably, Cgt ÿ/ÿ mice display defects in nerve conduction and die on postnatal days 18-30 from severe tremor and ataxia (Bosio et al., 1996; Coetzee et al., 1996) . We initially hypothesized that sulfatide contributed to the signals mediating HSPC mobilization. During the course of these studies, we found that Cgt ÿ/ÿ mice exhibit defects in postnatal lymphopoiesis owing to specific deficits in stromal elements that support the growth and differentiation of lymphoid precursors . Here, we report that Cgt ÿ/ÿ mice fail to mobilize BM HSPCs following G-CSF stimulation. Unexpectedly, the deficit is not due to the absence of BM sulfatide but likely originates from altered neural influence on osteoblasts. Indeed, we show that signals emanating from the sympathetic nervous system suppress osteoblast function and control the attraction of stem cells to their niche.
RESULTS
Mobilization Is Severely Impaired in Cgt ÿ/ÿ Mice Cgt littermates were treated with G-CSF to elicit HSPCs from the BM. Strikingly, there was little mobilization in Cgt ÿ/ÿ mice compared to Cgt +/ÿ or +/+ littermates ( Figure 1A ). The reduction of circulating HSPCs in Cgt ÿ/ÿ mice was not due to lower numbers of progenitors ( Figure 1B ) or stem cells ( Figure 1C ; see for competitive reconstitution) in the BM. However, the number of common lymphoid progenitor (CLP) cells (Kondo et al., 1997) was significantly reduced in Cgt ÿ/ÿ mice compared to Cgt +/+ littermates ( Figure 1C ), indicating that the previously reported block in lymphoid differentiation occurs before the CLP stage. To exclude the possibility that the lymphopenic state contributed to the impaired mobilization in Cgt ÿ/ÿ mice, we injected G-CSF in Rag1 ÿ/ÿ and IL7Ra ÿ/ÿ mice, which have broad deficits in B and T cells.
Circulating CFU-Cs were elicited at levels similar to those of wild-type mice (data not shown), indicating that the mobilization defect in Cgt ÿ/ÿ mice is unrelated to lymphopenia.
If fucoidan promoted HSPC mobilization by mimicking the function of endogenous sulfatide, we would expect that its administration in Cgt ÿ/ÿ mice might rescue the mobilization defect. To test this possibility, we treated Cgt littermates with fucoidan and assayed for circulating HSPCs. We found that CFU-Cs were not mobilized by fucoidan in Cgt ÿ/ÿ mice ( Figure 1D ), suggesting that Cgt expression is necessary for mobilization triggered by either fucoidan or G-CSF.
The Mobilization Defect Originates from the Stromal Compartment
It has been reported that HIV-1 entry into human intestinal epithelial cell lines can be blocked by either anti-GalCer or anti-CXCR4 mAbs, suggesting that CXCR4 can cooperate with GalCer during the fusion process (Delezay et al., 1997) . We assessed the migration of Cgt ÿ/ÿ BM mononuclear cells toward CXCL12 to investigate whether the mobilization defect arose from CXCR4 dysfunction on Cgt ÿ/ÿ hematopoietic cells. However, Cgt ÿ/ÿ and +/+ cells did not differ in CXCL12-mediated migration ( Figure 1E ). To evaluate further whether the defect in HSPC mobilization observed in Cgt ÿ/ÿ mice could originate from hematopoietic cells, Cgt +/+ or ÿ/ÿ BM nucleated cells (BMNCs;
CD45.2+) were transplanted into lethally irradiated wildtype CD45.1 congenic mice. G-CSF-induced mobilization was similar for highly chimeric (>95% of donor type) Cgt +/+ and ÿ/ÿ mice ( Figure 1F ). Thus, these results indicate that the mobilization defect cannot be transferred through the transplantation of BM-derived hematopoietic cells.
G-CSF-Induced Bone Marrow Proteolytic Activity
Is Preserved in Cgt ÿ/ÿ Mice Previous studies have revealed that G-CSF induces proteolytic activity in the extracellular BM microenvironment and that the released proteases, most notably neutrophil elastase, may play an important role in mobilization Levesque et al., 2003) . We found that neutrophil elastase activity in supernatants from phorbol-myristate acetate (PMA)-activated BMNCs was similar for Cgt +/+ and ÿ/ÿ littermates ( Figure 1G ), suggesting that Cgt ÿ/ÿ BMNCs have a normal capacity to produce and release this serine protease. To evaluate more globally the proteolytic environment in Cgt ÿ/ÿ mice, recombinant CXCL12 was incubated with BM extracellular fluid (BMEF) derived from PBS/BSA or G-CSF-treated mice, and the degradation of recombinant CXCL12 was assessed by immunoblotting. A slight degradation of CXCL12 by BMEF was observed in PBS/ BSA-treated mice, but no change was observed for Cgt protein was completely degraded after incubation with BMEF from G-CSF-treated Cgt +/+ mice ( Figure 1H , lane 3), and complete degradation also occurred with BMEF from G-CSF-treated Cgt ÿ/ÿ mice ( Figure 1H , lane 5). Thus, mobilization is impaired in Cgt ÿ/ÿ mice despite normal proteolysis in the BM.
CXCL12 Is Expressed in Bone
CXCL12 has been reported to be expressed by endothelial cells and osteoblasts using immunohistochemical staining of human BM samples, but the positively stained area was limited and sporadic (Ponomaryov et al., 2000; Petit et al., 2002) . Knockin mice expressing GFP driven within the cxcl12 locus exhibited a speckled distribution of fluorescent stromal cells in the BM (Tokoyoda et al., 2004) . We first performed standard immunofluorescence staining of CXCL12 in frozen sections of wild-type mouse BM but found no specific staining, likely due to the very low levels of CXCL12 in the BM (ng range in an entire femur) Levesque et al., 2003) . However, staining using the tyramide amplification system revealed a specific speckled staining in the BM parenchyma and, unexpectedly, strong and consistent staining in bone (Figures 2A-2F ). Bone CXCL12 was not restricted to the endosteal region, a putative location of the stem cell niche (Calvi et al., 2003; Zhang et al., 2003) , but was distributed throughout the entire thickness. To confirm further the staining specificity, we compared the expression of CXCL12 between BMEF and protein extracts from bone by ELISA. Total CXCL12 was in fact higher in bone extracts than in BMEF ( Figure 2G ), indicating that bone tissues are a major reservoir of CXCL12. To assess whether CXCL12 in bone was cell or matrix associated, we stained for CXCL12 and CD44, an osteocyte marker, but found no evidence of colocalization of the CXCL12 signal with osteocytes ( Figures 2H and 2I ). However, primary osteoblasts and the osteoblast precursor cell line ST2 express high levels of CXCL12 (Ponomaryov et al., 2000 and data not shown), indicating that CXCL12 is likely deposited in the bone matrix by osteoblasts but not osteocytes.
Decreased CXCL12 Expression in Bone Correlates with Mobilization CXCL12 levels decrease in BMEF during mobilization, and this effect has been suggested to induce cell egress. Therefore, we have determined CXCL12 levels by ELISA in the compact bone as well as in the BMEF of Cgt littermate mice treated with either control PBS/BSA or G-CSF. We confirmed that CXCL12 was greatly reduced in Cgt +/+ and +/ÿ BMEF after G-CSF injection ( Figure 3A) . Unexpectedly, the CXCL12 protein in Cgt ÿ/ÿ BMEF was also significantly reduced by G-CSF ( Figure 3A) , despite the fact that these mice do not mobilize HSPCs. While CXCL12 also decreased in the bone of normal littermate mice following G-CSF administration ( Figure 3B ), there was no reduction of CXCL12 protein levels in the bone of Cgt ÿ/ÿ mice. These results indicate that CXCL12 levels in bone may correlate better than that of BM with the release of HSPCs.
G-CSF-Induced Transcriptional Downregulation of CXCL12
While proteases can clearly degrade CXCL12 in vitro, the maintenance of bone CXCL12 levels in Cgt ÿ/ÿ mice despite a robust BM proteolytic activity suggests the contribution of other regulatory mechanisms. To assess whether CXCL12 is regulated at the transcriptional level, we evaluated the expression of the two major isoforms of CXCL12 (a and b) by quantitative real-time RT-PCR (Q-PCR) in bone and BM tissues of Cgt littermates. The mRNA expression of both CXCL12 isoforms was profoundly decreased in BM after G-CSF in both Cgt ÿ/ÿ and normal littermates ( Figures 3C and 3D). CXCL12 mRNA levels in bone were moderately decreased after G-CSF treatment (p < 0.05 for CXCL12a, p = 0.06 for CXCL12b). Although there was a trend toward decreased CXCL12 transcripts in Cgt ÿ/ÿ bone after G-CSF, the difference was not significant, and mRNA levels were still higher in G-CSF-treated Cgt ÿ/ÿ bone than those of steadystate normal littermates ( Figures 3C and 3D ). Thus, CXCL12 is transcriptionally regulated in both BM and bone tissues. Blunted transcriptional downregulation in Cgt ÿ/ÿ mice may contribute to the sustained CXCL12 protein levels in Cgt ÿ/ÿ bone.
Osteoblast Activity Is Altered in Cgt ÿ/ÿ Mice
We noted during the staining of osteocytes (Figures 2H and 2I) that bone lining osteoblasts in Cgt ÿ/ÿ mice were generally flat with little cytoplasm and short projections into bone, while osteoblasts from littermate controls displayed a homogenous cobblestone-like appearance sending numerous and deep projections into the bone matrix ( Figures 4A and 4B ). The osteoblast function was also altered in Cgt ÿ/ÿ mice since plasma osteocalcin levels were significantly reduced as compared with normal littermates ( Figure 4C ; 39% reduction, n = 6-9, p < 0.001). However, the number of apoptotic osteoblasts in Cgt ÿ/ÿ mice, as determined by TUNEL assay, was not increased (data not shown). Further, the absence of Cgt expression was not directly responsible for the osteoblast dysfunction since Cgt mRNA was not detected in various osteoblast lineage cells ( Figure 4D ). To confirm the absence of Cgt expression in osteoblastic cells, we cultured MC3T3-E1 and ST2 cell lines with ascorbic acid for 18 days to induce further maturation. Even under these differentiating conditions, no Cgt mRNA was detectable (Figures S1A and S1B). These results thus suggest that osteoblast function is altered in Cgt ÿ/ÿ mice through an indirect mechanism.
G-CSF Suppresses Osteoblast Activity
Considering the suppression of osteoblast activity in Cgt ÿ/ÿ mice and the fact that osteocalcin levels have been reported to be reduced after G-CSF administration (Takamatsu et al., 1998; Froberg et al., 1999) , we reasoned that HSPC mobilization by G-CSF may be caused by a rapid downregulation in osteoblast activity. We evaluated the effect of G-CSF administration on the expression of Runx2, a transcription factor controlling osteoblast function and a1(I) collagen, a major osteoblast gene product and component of the bone matrix. The expression of both genes was dramatically downregulated by G-CSF administration in the bone marrow of Cgt +/+ mice (Figures 4E and 4F; levels of Runx2; 65% reduction, n = 4, p < 0.001, a1(I) collagen; 92% reduction, n = 4, p < 0.05). However, in Cgt ÿ/ÿ mice, the steady-state levels of Runx2 and a1(I) collagen tended to be lower than control littermate mice, and the downregulation following G-CSF administration was not as marked (Figures 4E and 4F) . Strikingly, bone-lining osteoblasts in G-CSF-treated age-matched wild-type C57BL/6 mice resembled those from steady-state Cgt ÿ/ÿ mice ( Figure 4G ) and exhibited a flattened appearance with shorter projections into the bone matrix ( Figure 4H ). Since osteoblasts do not express G-CSFR ( Figure 4I ), these results indicate that G-CSF suppresses osteoblast activity through an indirect mechanism.
Signals from the Sympathetic Nervous System Trigger G-CSF-Induced Mobilization
Since Cgt ÿ/ÿ mice have severe neurological abnormalities (Coetzee et al., 1996; Bosio et al., 1996) , we explored the possibility that signals emanating from the nervous system participate in HSPC mobilization. This possibility would be consistent with data showing that adrenergic stimulation reduces bone formation, indicating that bone formation and osteoblast function are regulated by the sympathetic nervous system (SNS) (Takeda et al., 2002) . To test this hypothesis, we disrupted catecholaminergic neurons by serial perinatal injections of 6-hydroxydopamine (6OHDA) (Iversen et al., 1994) . 6OHDA treatment severely reduced the tissue content of catecholamines (Table S1 ). We found that the number of HSPCs mobilized by G-CSF was dramatically reduced in 6OHDA-lesioned mice compared to littermates injected with vehicle control ( Figure 5A ), even though 6OHDA did not alter baseline CFU-C counts per bone ( Figure 5B ). Strikingly, baseline bone-lining osteoblast morphology was similar between control and 6OHDA-treated mice (Figures 5C and 5E) . By contrast, G-CSF suppressed osteoblasts from control mice but not from 6OHDA-treated littermates ( Figures 5D and 5F ). Neonatal administration of 6OHDA damages both central and peripheral, dopaminergic and noradrenergic, neurons, owing to the permeable blood-brain barrier of newborn mice. To distinguish between the two catecholaminergic pathways, we studied mice deficient in dopamine b-hydro-
), the enzyme necessary for the conversion of dopamine into norepinephrine (NE) (Thomas et al., 1995) . G-CSF-triggered mobilization of CFU-Cs ( Figure 6A ) and the stem cell-enriched fraction (Lin ÿ Sca-1 + c-kit + cells; Figure 6B ) was dramatically compromised in Dbh ÿ/ÿ compared to Dbh +/ÿ littermates, indicating that noradrenergic neurons were required for mobilization by G-CSF. Immunohistological analyses of osteoblasts also revealed that morphology correlated with the effectiveness of G-CSF to induce mobilization, in that osteoblasts from G-CSF-treated Dbh +/ÿ mice exhibited a flattened appearance and shorter projections, whereas little change was observed in Dbh ÿ/ÿ mice ( Figures 6C-6F ). In addition, CXCL12 was reduced in bone protein extracts from Dbh +/ÿ mice following G-CSF administration, whereas CXCL12 levels were maintained in Dbh ÿ/ÿ animals ( Figure 6G ). Additionally, treatment of C57BL/6 mice for three weeks with a b blocker (propranolol) significantly reduced (> 20%) the number of HSPCs elicited by G-CSF ( Figure 6H ). To evaluate whether the mobilization defect in Dbh ÿ/ÿ mice could be rescued by the administration of a b 2 adrenergic agonist, we treated a separate cohort of Dbh +/ÿ and Dbh ÿ/ÿ animals with clenbuterol 2 days before and during G-CSF administration. Clenbuterol rescued in part the mobilization defect in Dbh ÿ/ÿ mice and, interestingly, further enhanced mobilization in Dbh +/ÿ controls (Figure 6I ). By contrast, administration of clenbuterol, by itself, at the same dose schedule did not trigger mobilization (data not shown), suggesting that b 2 adrenergic signaling is not downstream of but rather cooperates with other signals from the G-CSF receptor.
G-CSF Acts outside the Central Nervous System
Recent studies have revealed that G-CSF can cross the blood brain barrier and that the G-CSFR is widely expressed by neurons in the central nervous system (CNS) . That signals from the SNS originating from the hypothalamus can suppress bone formation also suggests the possibility of a G-CSF target in the CNS (Takeda et al., 2002) . To address this issue, we stereotaxically implanted guide cannulae into lateral ventricles of C57BL/6 mice. One week after implantation, mice received G-CSF either directly in the CNS by intracerebroventricular (ICV) infusion or systemically by s.c. injection. As shown in Figure 7A , robust HSPC mobilization occurred only when mice were treated systemically, indicating that the cellular target(s) of G-CSF lies in the periphery. Since 6OHDA does not penetrate the CNS of adult mice and causes transient damage of peripheral noradrenergic neurons (Livnat et al., 1985) , we also evaluated whether G-CSF elicited mobilization in adult 6OHDA-lesioned mice. We found that mobilization was significantly reduced in 6OHDA-treated adult mice ( Figure 7B ), confirming that a disruption of noradrenergic neurons arising from peripheral sympathetic ganglia is sufficient to impair the egress of HSPC.
NE in peripheral tissues is synthesized and stored in sympathetic nerve endings. In response to sympathetic nerve impulses, NE is released in the extracellular milieu to interact with its receptor target(s) and is then degraded or recycled. If G-CSF augmented NE release or disrupted its reuptake, we might expect a reduction in NE levels in tissues. To investigate this possibility, we measured NE by HPLC in hearts and bones of steady-state and G-CSF-treated C57BL/6 mice. While cardiac NE levels in mice that received a single dose of G-CSF were slightly reduced, we found a dramatic Wild-type fresh-frozen femoral bone transverse sections were stained with control goat IgG (A and B) or anti-CXCL12 antibody (C and D), followed by sequential amplification steps. (A) and (C) are differential interference contrast (DIC) images of (B) and (D) shown to delineate bone and BM tissues. An area of bone (square) is highlighted in (E) (DIC) and (F) (CXCL12). (G) CXCL12 protein levels determined by ELISA of BMEF and bone extracts from steady-state wild-type mice; n = 8 mice per group, *p < 0.05. (H and I) Bone section stained for CD44 (green) to visualize osteocytes and CXCL12 (red). The composite image (I) shows no apparent colocalization of staining. Black bar, 50 mm; white bar, 20 mm. reduction in bone NE levels 3 hr after G-CSF administration, suggesting that G-CSF may selectively stimulate the activity of the SNS in bone/BM tissues ( Figure 7C ). Thus, taken together, these data suggest that G-CSF-induced adrenergic signals emerging from the peripheral nervous system regulate the egress of stem/progenitor cells from their bone marrow niche ( Figure 7D ).
DISCUSSION

Regulated CXCL12 Expression in Bone
Several studies have suggested that a CXCL12 chemokine gradient between BM and blood, modifiable by secreted proteases, plays a key role in HSPC mobilization (Levesque et al., 2002; Petit et al., 2002) . That HSPC mobilization was virtually absent in Cgt ÿ/ÿ mice despite robust proteolytic activity in the BM led us to investigate alternative expression and regulation of CXCL12. Our studies suggest that CXCL12 is expressed at high levels in bone tissues and that bone CXCL12 is dysregulated in Cgt ÿ/ÿ mice following G-CSF administration. CXCL12 staining in bone matrix was specific, as shown by appropriate antibody controls and by confirmation with a sandwich ELISA. The fact that fluorescence staining in bone was not reported in knockin mice expressing GFP under the CXCL12 locus is likely due to differential sorting mechanisms for GFP and CXCL12 (Tokoyoda et al., 2004) . In addition, these results are consistent with a recent report documenting the presence of CXCL12 in bone (Sun et al., 2005) .
Although osteocytes represent the major cell type present in bone, they do not appear to synthesize CXCL12. Indeed, no colocalization between CXCL12 and osteocyte staining was observed in vivo ( Figure 2 ) and, in addition, an osteocytelike cell line (MLO-Y4 cells) (Kato et al., 1997) neither expresses CXCL12 mRNA nor secretes CXCL12 protein (Y.K. and P.S.F., unpublished data). BM CXCL12 has been reported to be expressed by endothelial cells, osteoblasts, and other stromal elements (Ponomaryov et al., 2000; Tokoyoda et al., 2004) . The presence of high concentrations of CXCL12 in bone and its striking downregulation with G-CSF-induced osteoblast suppression strongly suggest that it is primarily deposited by osteoblasts, like many other growth factors that are enriched in bone matrix (Hauschka et al., 1988) . Indeed, recent studies suggest that BM CXCL12 is largely produced by osteoblasts (Semerad et al., 2005) . Despite reduced osteoblastic activity, CXCL12 levels are preserved in bone tissues of Cgt ÿ/ÿ mice (Figure 3 ), suggesting alternative or compensatory mechanisms by other stromal elements unconstrained by neural control. Whereas CXCL12 is constitutively expressed in a variety of tissues and is necessary for vascular development, intriguing data have suggested that certain cytokines (e.g., TGF-b and TNF-a) can decrease CXCL12 transcript levels in stromal and fibroblastic cell lines via yet unidentified mechanisms (Fedyk et al., 2001; Wright et al., 2003) . TNF-a was a prime contender to mediate osteoblast suppression because it is reported to inhibit Runx2, a1(I) collagen, and osteocalcin (Nanes, 2003) and to be essential for CXCL12 downregulation in the BM during immunization (Ueda et al., 2004) . However, it is unlikely that TNF-a contributes to HSPC mobilization since G-CSF administration does not alter TNF-a mRNA levels in the BM and, more importantly, TNF-a-deficient mice mobilize normal numbers of HSPCs (Y.K. and P.S.F., unpublished data). Whether Runx2, a key transcription factor that controls the expression of multiple osteoblast genes, influences the expression of CXCL12 is being tested in the laboratory.
We have found no evidence that soluble GCs are involved in the survival, growth, or function of osteoblasts since (1) neither osteoblasts (Figure 4 ) nor hematopoietic cells express the Cgt gene; (2) neither the lymphopoietic nor the HSPC mobilization phenotype are transplantable Figure 1F) ; (3) GCs are not detectable in BMEF or mouse serum; (4) although Cgt mRNA can be detected by Q-PCR in BM and bone, GCs are not detectable by high performance thin layer chromatography, even when alkali-stable lipid extracts from more than 2 femurs are loaded (Figures S2A-S2C ). Thus we believe that the low expression level of Cgt in these organs originates from Schwann cells that support the transmission of neuronal signals.
Neuronal Regulation of the Stem Cell Niche
Neural control of bone metabolism, both trophic and atrophic, has been suggested by numerous experimental and clinical observations. A rich network of nerve fibers was described in bone and bone marrow tissues with a significant subset of fibers reaching stromal cells (Calvo, 1968; Yamazaki and Allen, 1990 ). Immunolabeling studies have revealed a close association between glutamate-, catecholamine-, or peptide-containing nerve fibers and osteoblasts or osteoclasts in the endosteum (Hohmann et al., 1986; Serre et al., 1999; Takeda et al., 2002) . Blockade of glutamate receptors was reported to reduce the DNA binding activity and expression of Runx2 in cultured osteoblasts (Hinoi et al., 2003) . Clinically, peripheral neuropathy in diabetes is an independent risk factor for lower bone mineral density (Rix et al., 1999) . On the other hand, hyperadrenergic activity and osteopenia are characteristic signs of a human disease commonly referred to as reflex sympathetic dystrophy. Therapeutic sympathectomy was formerly used to decrease the discrepancies in limb length in children affected with poliomyelitis, underscoring the possibility of a dual effect of bone innervation on bone formation (Ring, 1961) . The effect of the sympathetic nervous system on bone formation has only recently been elucidated using genetic models (Chien and Karsenty, 2005) . These studies revealed that leptin induced bone loss through SNS-derived signals originating in the ventromedial hypothalamic nuclei (Takeda et al., 2002) . The atrophic appearance of osteoblasts in both G-CSF-treated wild-type mice and steady-state Cgt ÿ/ÿ mice and the fact that osteoblasts do not express G-CSFR or Cgt genes strongly supported the possibility that the rapid G-CSF-mediated osteoblast suppression is controlled by the nervous system.
Several lines of evidence indeed indicate that sympathetic signals contribute to the dramatic reduction in osteoblast function that follows G-CSF administration. First, the administration of 6OHDA in neonatal or adult mice inhibited mobilization without toxicity to the HSPC content in the BM. Second, G-CSF-induced HSPC mobilization was severely altered in NE-deficient mice. Third, osteoblast function was suppressed by G-CSF in control mice but not in mice with impaired SNS activity. Fourth, mobilization efficiency correlated with bone CXCL12 levels that were suppressed in Dbh +/ÿ and preserved in Dbh ÿ/ÿ mice. Fifth, the administration of a b 2 adrenergic agonist rescued the mobilization defect in Dbh ÿ/ÿ mice and enhanced mobilization in control mice. Finally, administration of a b adrenergic antagonist significantly reduced mobilization. The lower inhibition observed with b blockers compared with neonate 6OHDA-treated or Dbh ÿ/ÿ mice may result from incomplete inhibition of noradrenergic signaling. Consistent with this possibility, pharmacologic inhibition of b adrenergic receptors did not affect (1) and a yet unidentified signal (2) mediate osteoblast (OB) suppression, thereby reducing the synthesis of CXCL12. Posttranslational mechanisms (degradation/inactivation) may also contribute to lowering CXCL12 levels to those permissive for HSPC egress from their niche. We propose that OB suppression and CXCL12 reduction lead to HSPC mobilization. In addition, it is possible that adrenergic neurotransmission also regulates HSPC mobilization through other mechanisms, given the newly identified non-OB stem cell niches (Kiel et al., 2005) . bone resorption to the extent observed for genetic ablation of the b 2 adrenergic receptor (Elefteriou et al., 2005) .
While we found a strong correlation between osteoblast suppression and HSPC mobilization, our studies do not prove a causal relationship. It is interesting that another stem cell niche was recently identified near endothelial cells (Kiel et al., 2005) . While it is temping to speculate that sympathetic innervation, which accompanies the BM vasculature, may regulate the endothelial stem cell niche, whether osteoblasts can influence the attraction of these stem cells in the BM is unknown.
The involvement of the SNS in HSPC mobilization suggested that the target of G-CSF may be extramedullary and may in fact be neuronal or glial. On the other hand, G-CSFR expression on a transplantable hematopoietic cell was shown to be required for G-CSF-induced mobilization (Liu et al., 2000) . Based on studies describing leptin-mediated neuronal control of osteoblast function (Takeda et al., 2002; Elefteriou et al., 2005) and the fact that leptin and G-CSF receptors display a high degree of homology (Tartaglia et al., 1995) , we have considered the possibility that G-CSF signals directly in the hypothalamus through the leptin receptor. However, expression of the leptin receptor does not appear to be required for HSPC mobilization since it proceeds normally in leptin receptor-deficient db/db mice (Figure S3 ). In addition, the impaired mobilization after ICV infusion of G-CSF or in mice that have a peripheral SNS defect (6OHDA-lesioned adult mice) indicates that the cellular target for G-CSF is in the periphery.
Our results suggest that G-CSF may increase sympathetic tone in bone and that both G-CSF and adrenergic signaling cooperate to trigger HSPC egress ( Figure 7D ). Supporting evidence for a cooperation between these signals comes from the fact that clenbuterol does not by itself induce mobilization but that it can rescue at least in part the defect in Dbh ÿ/ÿ mice and enhance the mobilizing effects of G-CSF in Dbh +/ÿ mice. Whether G-CSF can modulate the release/ reuptake of NE by acting directly on neurons of sympathetic ganglia or via neighboring glial cells is currently unknown.
Trophic Neuronal Signals to Osteoblast
The constitutive suppression of osteoblast function in Cgt ÿ/ÿ mice might be due to increased sympathetic tone (Takeda et al., 2002) or, alternatively, a reduction in putative neurally transmitted trophic signals. Osteoblasts have been reported to express receptors for several neuropeptides, suggesting that they could indeed integrate multiple neuronal signals (Togari, 2002) . We have measured NE turnover in cardiac tissues of Cgt littermates and found a longer halflife in Cgt ÿ/ÿ hearts, indicating reduced peripheral sympathetic activity in the null mice ( Figure S4 (Visnjic et al., 2004) , indicating that the earliest committed lymphoid progenitor cell may require osteoblasts for survival, proliferation, or differentiation. A close relationship between CLP and the stem cell niche is further suggested by the expression of the Notch-1 ligand, Jagged-1, in the osteoblastic niche and the fact that Notch-1 can promote both stem cell self-renewal and differentiation toward the lymphoid lineage (Calvi et al., 2003; Pui et al., 1999; Radtke et al., 1999) . More differentiated B cell precursors (B220+flk2+), distant from the endosteum, are closely associated with CXCL12-expressing stromal cells, which do not express the Notch-1 ligands Jagged-1 or Delta-like-1 (Tokoyoda et al., 2004) . Further studies are thus needed to determine whether the nervous system influences homeostatic migration of stem cells among cellular niches in the BM. In summary, we show here that the sympathetic nervous system regulates the egress of stem and progenitor cells from their niche. These results raise the interesting possibility that alterations in the sympathetic tone may explain the conspicuous variability in mobilization efficiencies among normal donors (Korbling et al., 1995) . Modulation of the sympathetic outflow to the stem cell niche represents a novel strategy to increase the efficiency of HSPC harvests for stem cell-based therapeutics.
EXPERIMENTAL PROCEDURES
Animals Cgt
, and ÿ/ÿ littermate mice, backcrossed seven generations into the C57BL/6 background, were used for experiments performed between 3 and 4 weeks of age. Genotype was determined at weaning by PCR as described (Coetzee et al., 1996) . C57BL/6-CD45.1 congenic mice were purchased from Charles River Laboratories (Frederick Cancer Research Center, Frederick, MD) . Dbh littermate mice were bred and rescued with L-threo-3,4-dihydroxyphenylserine (L-DOPS, Sumitomo Pharmaceuticals, Osaka, Japan) as described in Supplemental Experimental Procedures. Mice were housed at Mount Sinai School of Medicine, where experimental procedures were approved by the IACUC.
Mobilization of Hematopoietic Progenitors
To induce HSPC mobilization, mice were injected with recombinant human G-CSF (Filgrastim, Amgen, Thousand Oaks, CA, 250 mg/kg/day, every 12 hr, 8 divided doses, s.c.) in PBS supplemented with 0.1% endotoxin-free bovine serum albumin (BSA) or fucoidan (Sigma; 2 doses of 100 mg/kg with 2 hr interval, i.p.) in PBS. Blood was harvested 3 hr (G-CSF) or 1 hr (fucoidan). CFU-C assays were carried out as previously described .
Intracerebroventricular G-CSF Infusion
A chronic guide cannula (1.0 mm) was implanted stereotaxically into the lateral ventricle (coordinates AP, ÿ0.7 mm; DV, ÿ2.4 mm; ML, 1.5 mm, from bregma). One week after implantation, mice received a reduced dose of G-CSF (25 mg/kg daily for 4 doses) either by ICV infusion (rate: 0.4 ml/min) or by s.c. injection.
Pharmacological Disruption or Induction of SNS-Signals
Newborn C57BL/6 mice were injected s.c. with 6OHDA (100 mg/kg, Sigma) or vehicle (saline) on postnatal days 2, 4, 6, 8, and 9. HSPC mobilization was induced at 3 weeks of age. For SNS disruption in adult C57BL/6 mice, 4-week-old animals were injected i.p. with 2 doses of 6OHDA or vehicle, 100 mg/kg on day 0, 250 mg/kg on day 2, and G-CSF treatment was begun on day 5. For b adrenergic receptor blockade, 4-week-old C57BL/6 mice were treated with propranolol (0.5 g/l in drinking water, Sigma) or control pure water for 3 weeks prior to mobilization. For rescue experiments, clenbuterol (2 mg/kg/day, i.p.) was injected starting day ÿ2 prior to and continued during G-CSF treatment.
Generation of Chimeric Mice
Chimeric mice were generated by injection of 1 Â 10 6 Cgt +/+ or ÿ/ÿ mice (CD45.2) BMNCs into lethally irradiated (12 Gy, split dose) C57BL/6-CD45.1 congenic mice (Frenette and Weiss, 2000) .
Migration Assay and Enzymatic Release
Transwell migration and elastase release assays were performed as described (Hidalgo et al., 2004) .
ELISA CXCL12 ELISA was done exactly as described . Mouse plasma osteocalcin was measured using ELISA kit (Biomedical Technologies Inc., Stoughton, MA) according to manufacturer's recommendation.
Flow Cytometry and Immunofluorescence Microscopy
Detailed methods for flow cytometry and immunofluorescence analyses of bone sections are available in Supplemental Experimental Procedures.
Bone Protein Extraction, Catecholamine Measurements, and Western Blot Analyses Protein extraction from bone, biogenic amine determination, BM, and CXCL12 immunoblotting were carried out as detailed in Supplemental Experimental Procedures.
RNA Extraction and Q-PCR
Methods, primers, and PCR conditions are available in Supplemental Experimental Procedures and Table S3 .
Statistical Analysis
All values are reported as mean ± SEM. Statistical significance for two unpaired groups was assessed by the Student's t test or Mann-Whitney U test. Significance was set at p < 0.05.
Supplemental Data
Supplemental Data include four figures, three tables, Experimental Procedures, and References and can be found with this article online at http:// www.cell.com/cgi/content/full/124/2/407/DC1/.
